Annotation Detail

Information
Associated Genes
ERBB2
Associated Variants
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
Efficacy of trastuzumab in HER2 overexpressing NSCLC remains unclear. In this study using a panel of NSCLC HER2 overexpressing cell lines, antiproliferative effects of trastuzumab emtansine (T-DM1) were observed in a HER2-expression dependant manner, with strongest effects in Calu-3 (high expressing) and no effects in Calu-6 (low expressing). Trastuzumab did not show notable effects on cell growth in any tested cells. HER2 positivity in NSCLC is fairly common at 2-20%. A clinical trial (NCT02289833) is currently underway to asses TDM-1 in HER2 overexpressing lung cancer.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1050
Gene URL
https://civic.genome.wustl.edu/links/genes/20
Variant URL
https://civic.genome.wustl.edu/links/variants/306
Rating
4
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Trastuzumab Emtansine
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
24898067
Drugs
Drug NameSensitivitySupported
Trastuzumab EmtansineSensitivitytrue